The cuvitru market research report is one of a series of new reports that provides cuvitru market statistics, including the cuvitru industry's global market size, regional shares, competitors with a cuvitru market share, detailed cuvitru market segments, market trends and opportunities, and any further data you may need to thrive in the cuvitru industry. This cuvitru market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing prevalence of immunodeficiencies, rising awareness about the benefits of immunoglobulin therapies, growing healthcare access, expansion of homecare settings for immunoglobulin administration, rising government support for healthcare and patient care, and rising aging global population. Major trends in the forecast period include development of more efficient subcutaneous infusion systems, innovations in home self-administration devices, advancements in patient monitoring system, integration of AI in managing personalized treatment plans, and advancements in formulations.
The increasing prevalence of immunodeficiency diseases is expected to drive the growth of the cuvitru market in the future. Immunodeficiency diseases are conditions in which the immune system fails to function properly, leaving individuals more vulnerable to infections and other health complications. Several factors contribute to the rise in these diseases, including improved diagnostic techniques that lead to higher detection rates, environmental influences such as pollution and climate change that affect immune function, and an aging population more susceptible to immune system decline. Cuvitru plays a critical role in treating these diseases by providing subcutaneous immunoglobulin replacement therapy, which helps restore the immune system and reduce the severity and frequency of infections in individuals with primary and secondary immunodeficiencies. In 2023, the Immune Deficiency Foundation reported that 1,177 patients were living with primary immunodeficiency, with common variable immunodeficiency (CVID) being the most prevalent diagnosis at 62%. As a result, the increasing prevalence of immunodeficiency diseases will contribute to the market's growth.
Rising healthcare spending is anticipated to drive the cuvitru market forward. Healthcare spending refers to the financial resources allocated by governments, organizations, and individuals for healthcare services, including medical treatments, hospital care, and pharmaceuticals. The increase in healthcare expenditure is driven by factors such as the growing prevalence of chronic diseases, aging populations, technological advancements in healthcare, and the need for enhanced access to medical services. This increased spending helps improve access to advanced immunoglobulin therapies, making treatments such as cuvitru more available to individuals with immune deficiencies. For example, a report published by the Health Foundation in November 2024 revealed that NHS England’s funding is set to increase from £171 billion ($216.1 billion) in 2023/24 to £192 billion ($242.64 billion) by 2025/26. The rising healthcare spending will therefore support the growth of the cuvitru market.
The growth of the aging population is also expected to contribute to the expansion of the cuvitru market. As the population ages, individuals aged 65 and older face various age-related challenges, such as weakened immune systems. The increase in the elderly population is largely due to improved healthcare, better living standards, and advancements in medical treatments, leading to longer life expectancies. Cuvitru is used in older adults to treat primary immunodeficiency, providing immunoglobulin replacement therapy to strengthen compromised immune systems. A report by the Population Reference Bureau in January 2024 estimated that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, a 47% increase. This shift will also lead to a higher proportion of this age group within the total U.S. population, growing from 17% to 23%. Therefore, the growing aging population will further propel the growth of the cuvitru market.
The countries covered in the cuvitru market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Cuvitru is an immunoglobulin-based medication that contains human immune globulin, designed to treat primary immunodeficiencies. It helps individuals with compromised immune systems by providing the antibodies that their bodies cannot produce. This medication replenishes antibodies in patients suffering from conditions such as chronic granulomatous disease or severe combined immunodeficiency.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Cuvitru include common variable immunodeficiency (CVID), x-linked agammaglobulinemia, and severe combined immunodeficiency (SCID). CVID is a condition that leads to reduced antibody production and frequent infections, and Cuvitru helps manage it by restoring antibody levels through immunoglobulin replacement therapy. Cuvitru is distributed through multiple channels, including hospital pharmacies, specialty pharmacies, and home healthcare providers. It is used in various settings such as clinics, hospitals, and homecare environments.
The cuvitru market consists of sales of human immune globulin solution, infusion pumps, needles and syringes, and IV sets and tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing prevalence of immunodeficiencies, rising awareness about the benefits of immunoglobulin therapies, growing healthcare access, expansion of homecare settings for immunoglobulin administration, rising government support for healthcare and patient care, and rising aging global population. Major trends in the forecast period include development of more efficient subcutaneous infusion systems, innovations in home self-administration devices, advancements in patient monitoring system, integration of AI in managing personalized treatment plans, and advancements in formulations.
The increasing prevalence of immunodeficiency diseases is expected to drive the growth of the cuvitru market in the future. Immunodeficiency diseases are conditions in which the immune system fails to function properly, leaving individuals more vulnerable to infections and other health complications. Several factors contribute to the rise in these diseases, including improved diagnostic techniques that lead to higher detection rates, environmental influences such as pollution and climate change that affect immune function, and an aging population more susceptible to immune system decline. Cuvitru plays a critical role in treating these diseases by providing subcutaneous immunoglobulin replacement therapy, which helps restore the immune system and reduce the severity and frequency of infections in individuals with primary and secondary immunodeficiencies. In 2023, the Immune Deficiency Foundation reported that 1,177 patients were living with primary immunodeficiency, with common variable immunodeficiency (CVID) being the most prevalent diagnosis at 62%. As a result, the increasing prevalence of immunodeficiency diseases will contribute to the market's growth.
Rising healthcare spending is anticipated to drive the cuvitru market forward. Healthcare spending refers to the financial resources allocated by governments, organizations, and individuals for healthcare services, including medical treatments, hospital care, and pharmaceuticals. The increase in healthcare expenditure is driven by factors such as the growing prevalence of chronic diseases, aging populations, technological advancements in healthcare, and the need for enhanced access to medical services. This increased spending helps improve access to advanced immunoglobulin therapies, making treatments such as cuvitru more available to individuals with immune deficiencies. For example, a report published by the Health Foundation in November 2024 revealed that NHS England’s funding is set to increase from £171 billion ($216.1 billion) in 2023/24 to £192 billion ($242.64 billion) by 2025/26. The rising healthcare spending will therefore support the growth of the cuvitru market.
The growth of the aging population is also expected to contribute to the expansion of the cuvitru market. As the population ages, individuals aged 65 and older face various age-related challenges, such as weakened immune systems. The increase in the elderly population is largely due to improved healthcare, better living standards, and advancements in medical treatments, leading to longer life expectancies. Cuvitru is used in older adults to treat primary immunodeficiency, providing immunoglobulin replacement therapy to strengthen compromised immune systems. A report by the Population Reference Bureau in January 2024 estimated that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, a 47% increase. This shift will also lead to a higher proportion of this age group within the total U.S. population, growing from 17% to 23%. Therefore, the growing aging population will further propel the growth of the cuvitru market.
The key company operating in the cuvitru market is Takeda Pharmaceutical Company Limited (Baxalta US Inc.)
Asia-Pacific was the largest region in the cuvitru market in 2024. The regions covered in cuvitru report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the cuvitru market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Cuvitru is an immunoglobulin-based medication that contains human immune globulin, designed to treat primary immunodeficiencies. It helps individuals with compromised immune systems by providing the antibodies that their bodies cannot produce. This medication replenishes antibodies in patients suffering from conditions such as chronic granulomatous disease or severe combined immunodeficiency.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Cuvitru include common variable immunodeficiency (CVID), x-linked agammaglobulinemia, and severe combined immunodeficiency (SCID). CVID is a condition that leads to reduced antibody production and frequent infections, and Cuvitru helps manage it by restoring antibody levels through immunoglobulin replacement therapy. Cuvitru is distributed through multiple channels, including hospital pharmacies, specialty pharmacies, and home healthcare providers. It is used in various settings such as clinics, hospitals, and homecare environments.
The cuvitru market consists of sales of human immune globulin solution, infusion pumps, needles and syringes, and IV sets and tubing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cuvitru Market Characteristics4. Cuvitru Market Trends And Strategies5. Cuvitru Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Cuvitru Pricing Analysis & Forecasts30. Global Cuvitru Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Cuvitru Market32. Recent Developments In The Cuvitru Market
3. Cuvitru Market Biologic Drug Characteristics
6. Global Cuvitru Growth Analysis And Strategic Analysis Framework
8. Cuvitru Market Segmentation
9. Global Cuvitru Epidemiology Of Clinical Indications
10. Cuvitru Market Regional And Country Analysis
11. Asia-Pacific Cuvitru Market
12. China Cuvitru Market
13. India Cuvitru Market
14. Japan Cuvitru Market
15. Australia Cuvitru Market
16. South Korea Cuvitru Market
17. Western Europe Cuvitru Market
18. UK Cuvitru Market
19. Germany Cuvitru Market
20. France Cuvitru Market
21. Eastern Europe Cuvitru Market
22. North America Cuvitru Market
23. USA Cuvitru Market
24. Canada Cuvitru Market
25. South America Cuvitru Market
26. Middle East Cuvitru Market
27. Africa Cuvitru Market
28. Cuvitru Market Competitive Landscape And Company Profiles
29. Global Cuvitru Market Pipeline Analysis
33. Cuvitru Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Cuvitru Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cuvitru market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cuvitru ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cuvitru market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Common Variable Immunodeficiency (CVID); X-Linked Agammaglobulinemia; Severe Combined Immunodeficiency (SCID)2) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Home Healthcare Providers
3) By End-Use: Clinics; Homecare; Hospitals; Other End-Uses
Key Companies Profiled: Takeda Pharmaceutical Company Limited (Baxalta US Inc.)
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Takeda Pharmaceutical Company Limited (Baxalta US Inc.)
